Editorial
doi: 10.1200/JCO.2008.19.5024.
Epub 2008 Nov 10.
Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies
- PMID: 19001346
- DOI: 10.1200/JCO.2008.19.5024
Item in Clipboard
Editorial
Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies
J Clin Oncol.
.
Erratum in
- J Clin Oncol. 2009 Jun 20;27(18):3070
No abstract available
Comment on
-
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10. J Clin Oncol. 2008. PMID: 19001320
Similar articles
-
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10. J Clin Oncol. 2008. PMID: 19001320
-
Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies.J Clin Oncol. 2010 Oct 1;28(28):e529-31; author reply e532-e533. doi: 10.1200/JCO.2010.29.5626. Epub 2010 Aug 2. J Clin Oncol. 2010. PMID: 20679615 No abstract available.
-
The forest and the trees: pathways and proteins as colorectal cancer biomarkers.J Clin Oncol. 2009 Dec 10;27(35):5866-7. doi: 10.1200/JCO.2009.24.8013. Epub 2009 Nov 2. J Clin Oncol. 2009. PMID: 19884524 No abstract available.
-
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?Cancer Treat Rev. 2010 Nov;36 Suppl 3:S56-61. doi: 10.1016/S0305-7372(10)70021-9. Cancer Treat Rev. 2010. PMID: 21129611 Review.
-
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.J Clin Oncol. 2010 Mar 1;28(7):1254-61. doi: 10.1200/JCO.2009.24.6116. Epub 2010 Jan 25. J Clin Oncol. 2010. PMID: 20100961 Review.
Cited by
-
KRAS mutations and subtyping in colorectal cancer in Jordanian patients.Oncol Lett. 2012 Oct;4(4):705-710. doi: 10.3892/ol.2012.785. Epub 2012 Jul 4. Oncol Lett. 2012. PMID: 23205087 Free PMC article.
-
Regulation of IFN-γ-mediated PD-L1 expression by MYC in colorectal cancer with wild-type KRAS and TP53 and its clinical implications.Front Pharmacol. 2022 Dec 13;13:1022129. doi: 10.3389/fphar.2022.1022129. eCollection 2022. Front Pharmacol. 2022. PMID: 36582540 Free PMC article.
-
Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.Tumour Biol. 2011 Apr;32(2):417-24. doi: 10.1007/s13277-010-0136-3. Epub 2010 Nov 23. Tumour Biol. 2011. PMID: 21104178
-
Molecular genetics of microsatellite-unstable colorectal cancer for pathologists.Diagn Pathol. 2017 Mar 4;12(1):24. doi: 10.1186/s13000-017-0613-8. Diagn Pathol. 2017. PMID: 28259170 Free PMC article. Review.
-
Colorectal Cancer Biomarkers: Where Are We Now?Biomed Res Int. 2015;2015:149014. doi: 10.1155/2015/149014. Epub 2015 May 27. Biomed Res Int. 2015. PMID: 26106599 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
